Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Free Cash Flow (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Free Cash Flow data on record, last reported at -$69.5 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 21.18% year-over-year to -$69.5 million; the TTM value through Dec 2025 reached -$323.0 million, down 17.51%, while the annual FY2025 figure was -$323.2 million, 17.56% down from the prior year.
  • Free Cash Flow reached -$69.5 million in Q4 2025 per SNDX's latest filing, up from -$70.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $100.7 million in Q4 2021 and bottomed at -$95.2 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$43.2 million, with a median of -$41.6 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: soared 744.29% in 2021, then crashed 122.73% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $100.7 million in 2021, then plummeted by 122.73% to -$22.9 million in 2022, then crashed by 80.61% to -$41.3 million in 2023, then tumbled by 38.79% to -$57.4 million in 2024, then dropped by 21.18% to -$69.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$69.5 million in Q4 2025, -$70.5 million in Q3 2025, and -$87.8 million in Q2 2025.